Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,678,980 shares of the medical research company's stock after acquiring an additional 69,885 shares during the quarter. Thermo Fisher Scientific comprises 0.8% of Schroder Investment Management Group's holdings, making the stock its 20th largest holding. Schroder Investment Management Group owned approximately 0.44% of Thermo Fisher Scientific worth $873,456,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at approximately $26,000. Barrett & Company Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $28,000. Missouri Trust & Investment Co acquired a new position in Thermo Fisher Scientific during the 4th quarter worth about $29,000. Finally, Pillar Financial Advisors LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company's stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock valued at $13,106,062 over the last quarter. Corporate insiders own 0.34% of the company's stock.

Remove Ads

Thermo Fisher Scientific Stock Performance

NYSE TMO traded down $15.09 during trading on Tuesday, reaching $482.51. The company's stock had a trading volume of 1,837,520 shares, compared to its average volume of 1,620,453. The business's fifty day moving average price is $540.37 and its 200-day moving average price is $551.02. Thermo Fisher Scientific Inc. has a twelve month low of $481.47 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market cap of $182.03 billion, a price-to-earnings ratio of 29.19, a P/E/G ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.36%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is presently 10.41%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TMO shares. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. UBS Group upped their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Wells Fargo & Company lifted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Bank of America reduced their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Finally, Scotiabank boosted their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.